Goldman Sachs bought 1,37,590 shares of Emcure Pharmaceuticals Limited for ₹25.00 Cr at ₹1817.00 apiece in a block deal.
A global pharmaceutical manufacturer established in 1981, Emcure Pharmaceuticals produces and markets a comprehensive range of drug formulations across multiple therapeutic areas for domestic and international markets. The company operates manufacturing facilities that serve patients globally, focusing on both generic and specialty pharmaceutical products. Emcure's diversified operations and geographic presence establish it as a significant player in the pharmaceutical industry.
US-based global investment bank (USD 1.6 trillion in assets, USD 3 trillion+ in client AUM through Goldman Sachs Asset Management). India FPI activity covers proprietary, market-making, client flows and active asset management mandates in listed Indian equities.
